Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study

• Tobita Hiroshi

  Division of Hepatology, Shimane University Hospital Department of Internal Medicine II, Shimane University School of Medicine

• Yazaki Tomotaka

  Division of Hepatology, Shimane University Hospital Department of Internal Medicine II, Shimane University School of Medicine

• Kataoka Masatoshi

  Division of Hepatology, Shimane University Hospital Department of Internal Medicine II, Shimane University School of Medicine

• Kotani Satoshi

  Department of Internal Medicine II, Shimane University School of Medicine

• Oka Akihiko

  Department of Internal Medicine II, Shimane University School of Medicine

• Mishiro Tsuyoshi

  Department of Internal Medicine II, Shimane University School of Medicine

• Oshima Naoki

  Department of Internal Medicine II, Shimane University School of Medicine

• Kawashima Kousaku

  Department of Internal Medicine II, Shimane University School of Medicine

• Ishimura Norihisa

  Department of Internal Medicine II, Shimane University School of Medicine

• Naora Kohji

  Department of Pharmacy, Shimane University Hospital

• Sato Shuichi

  Department of International Medicine, Izumo City General Medical Center

• Ishihara Shunji

  Department of Internal Medicine II, Shimane University School of Medicine

抄録

There are no reports regarding the efficacy of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and dipeptidyl peptidase 4 inhibitor (DPP4i) administrations in nonalcoholic fatty liver disease (NAFLD) patients without type 2 diabetes mellitus. The purpose of this study was to evaluate the efficacy of those drugs in such patients. NAFLD patients without type 2 diabetes mellitus were enrolled in this single center double-blind randomized prospective study, and allocated to receive either dapagliflozin (SGLT2i) or teneligliptin (DPP4i) for 12 weeks. Laboratory variables and body compositions were assessed at the baseline and end of treatment. The primary endpoint was alanine aminotransferase (ALT) reduction level at the end of treatment. Twenty-two eligible patients (dapagliflozin group, n = 12; teneligliptin group, n = 10) were analyzed. In both groups, the serum concentration of ALT was significantly decreased after treatment (p<0.05). Multiple regression analysis results showed that decreased body weight of patients with dapagliflozin administration was significantly related to changes in total body water and body fat mass. Administration of dapagliflozin or teneligliptin decreased the serum concentration of ALT in NAFLD patients without type 2 diabetes mellitus. With dapagliflozin, body weight decreased, which was related to changes in total body water and body fat mass (UMIN000027304).

収録刊行物

• Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｂｉｏｃｈｅｍｉｓｔｒｙ　ａｎｄ　Ｎｕｔｒｉｔｉｏｎ

  Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｂｉｏｃｈｅｍｉｓｔｒｙ　ａｎｄ　Ｎｕｔｒｉｔｉｏｎ 68 (2), 173-180, 2021-03-01

  一般社団法人　日本酸化ストレス学会

キーワード

• nonalcoholic fatty liver disease
• dapagliflozin
• teneligliptin
• alanine aminotransferase

詳細情報

• CRID: 1390287297545821696
• NII論文ID: 130007993437
• DOI: 10.3164/jcbn.20-129
• ISSN: 18805086
• ISSN: 09120009
• Web Site: https://www.jstage.jst.go.jp/article/jcbn/68/2/68_20-129/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2022122675
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可